JUNS stock sees best single-day gains in almost a year on $100M MDMA drug licensing deal – retail expects shares to hit $1

Jupiter Neurosciences, Inc. (JUNS) experienced its largest single-day gain in nearly a year, surging over 50% after securing a $100 million licensing deal for the MDMA-based drug ALA-002. The agreement includes a $3.3 million upfront payment and positions JUNS to capitalize on the growing psychedelic therapeutics market. Retail sentiment has turned extremely bullish, with expectations for shares to reach $1 despite a 60% decline this year.